# US 2005/0233452 A1 · Cell populations which co-express CD49c and CD90

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233452 A1
- Document ID: US20050233452A1
- Status: Published application
- Kind: A1
- Application number: 11/054,824
- Filed: 2005-02-10
- Published: 2005-10-20
- Earliest claimed: 2001-09-21
- Assignees: Neuronyx, Inc.
- Inventors: Tony Ho; Gene Kopen; William Righter; J. Rutkowski; Joseph Wagner
- Web page: https://patentgrep.com/patent/US20050233452A1

## CPC

- C12N 5/0669: {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N5/0647, C12N5/0663)}
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0623: {Stem cells}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2500/02: Atmosphere, e.g. low oxygen conditions
- C12N 2500/32: Amino acids
- C12N 2506/1353: from bone marrow mesenchymal stem cells (BM-MSC)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.

## Claims

### Claim 1

A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
a) culturing a source of the cell population at a seeding density of less than about 100 cells/cm2 under a low oxygen condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

### Claim 2 (depends on 1)

The method of claim 1, wherein the source of the cell population is bone marrow.

### Claim 3 (depends on 1)

The method of claim 1, wherein the bone marrow is human bone marrow.

### Claim 4 (depends on 1)

The method of claim 1, wherein the low oxygen condition is less than about 15% oxygen.

### Claim 5 (depends on 4)

The method of claim 4, wherein the low oxygen condition is about is less than about 10% oxygen.

### Claim 6 (depends on 1)

The method of claim 1, wherein the low oxygen condition is about 5% oxygen.

### Claim 7 (depends on 2)

The method of claim 2, further including lysing the bone marrow prior to culturing the bone marrow.

### Claim 8 (depends on 2)

The method of claim 2, further including fractionating the bone marrow prior to culturing the bone marrow.

### Claim 9 (depends on 8)

The method of claim 8, wherein in the bone marrow is fractionated by passage through a density gradient.

### Claim 10 (depends on 8)

The method of claim 8, wherein the bone marrow is fractionated by NH2Cl lysis.

### Claim 11 (depends on 8)

The method of claim 8, wherein the bone marrow is fractionated by fluorescent activated sorting.

### Claim 12 (depends on 8)

The method of claim 8, wherein the bone marrow is fractionated by magnetic sorting.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cells which co-express CD49c and CD90 do not express CD34 and/or CD45.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cells selected from the cultured source express at least one trophic factor selected from the group consisting of BDNF, IL-6, NGF and MCP-1.

### Claim 15

A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
a) culturing a source of the cell population at a seeding density of less than about 100 cells/cm2 under a low oxidative stress condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

### Claim 16 (depends on 15)

The method of claim 15, wherein the source of the cell population is bone marrow.

### Claim 17 (depends on 15)

The method of claim 15, wherein the bone marrow is human bone marrow.

### Claim 18

A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
a) culturing a source of the cell population at a seeding density of less than about 50 cells/cm2 under a low oxidative stress condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

### Claim 19

A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
a) culturing a source of the cell population at a seeding density of less than about 30 cells/cm2 under a low oxidative stress condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

### Claim 20

A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
a) culturing a source of the cell population at a seeding density of less than about 50 cells/cm2 under a low oxygen condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

### Claim 21

A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
a) culturing a source of the cell population at a seeding density of less than about 30 cells/cm2 under a low oxygen condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.
